St. Jude Medical to Highlight Comprehensive Arrhythmia Management Solutions and Electronic Health Record Connectivity at Heart Rhythm 2009

St. Jude Medical, Inc. (NYSE:STJ) today announced it will display a number of new products and technologies at the annual Heart Rhythm Society meeting in Boston this week, highlighting the company’s commitment to providing the most comprehensive and technologically advanced portfolio of therapies and devices for the treatment of heart arrhythmias, including products enabled with wireless connectivity. Devices and technologies are on display and are available for demonstration at the St. Jude Medical booth (#603).

St. Jude Medical remains uniquely focused on electrophysiology treatment options and is demonstrating its leadership in this area by sponsoring research that addresses clinical concerns facing the medical community and offering a complete range of arrhythmia management solutions. At Heart Rhythm 2009, St. Jude Medical will launch and demonstrate several new technologies for the treatment of arrhythmias, including:

• Current® Plus and Promote® Plus devices – the Current Plus implantable cardioverter defibrillator (ICD) and Promote Plus cardiac resynchronization therapy defibrillator (CRT-D) offer new alert features for atrial tachycardia and atrial fibrillation, and are available with the new SJ4 connector system that is designed to simplify implant procedures.
• SJM Confirm™ ICM – this implantable cardiac monitor (ICM) offers detailed and comprehensive data about patients’ heart conditions, particularly those patients who have challenging conditions to diagnose.
• Therapy™ Cool Path™ irrigated ablation catheter – with approved tip technology designed to allow for low irrigation fluid flow rates and the potential to maintain lower tip-to-tissue temperatures while allowing for wider and deeper lesions, the catheter is designed for effective therapy delivery.
• High density diagnostic catheters – multi-loop, multi-electrode catheters for high density electroanatomical mapping that are integrated with the EnSite™ System for seamless, enhanced diagnosis and visualization.

St. Jude Medical believes that critical to successful arrhythmia management is successful patient management. To help physicians more efficiently and effectively manage patient information, St. Jude Medical will highlight in the center of its booth the Merlin.net™ Patient Care Network (PCN) and Merlin@home® transmitter, and will demonstrate how these systems seamlessly connect with electronic health records. In addition, St. Jude Medical will feature other connectivity technology such as:

• EP-WorkMate™ – a cardiac recording system that integrates a cardiac stimulator and works seamlessly with HL-7 compliant data sources, such as many electronic health record systems. The system features ClearWave™ technology – a best-in-class technology for high-definition cardiac signals – and simultaneous nurse charting with the EPNurseMate ™ Remote Review Station.
• Merlin.net™ PCN – the most recent version of Merlin.net PCN features DirectCall® messages in multiple languages, an automated voice recording that, when set up, automatically calls patients to remind them of a remote follow-up appointment or a missed appointment, confirms their information was delivered to the physician, or asks them to call the office.

In the International portion of the booth, St. Jude Medical will feature the following arrhythmia management and connectivity technologies that were recently approved in Europe:

• Accent™ and Anthem™ RF Pacemakers – the company’s next step toward health care connectivity, the Accent and Anthem RF pacemaker family is the first complete pacemaker family with automatic test results and complete diagnostics that can be accessed via wireless communication in a clinic or remotely. Both the Accent pacemaker and the Anthem CRT-P will also allow physicians to monitor and be alerted when their patients with these devices are experiencing atrial fibrillation or atrial tachycardia.
• Current Accel™, AnalyST Accel™, and Promote Accel™ devices – newest St. Jude Medical high-voltage device family. By providing ongoing patient monitoring and automatic therapy adjustment, the Promote Accel CRT-D and Current Accel and AnalyST Accel ICDs tailor therapy to changing patient needs for increased safety and more efficient patient management.
• Therapy™ Cool Path™ DUO – the next step in advanced irrigated RF ablation catheters. With 12 irrigation ports on the tip (six additional holes), is designed to allow for even more uniform temperature distribution that may lead to more effective creation of wider and deeper lesions.
• SensiTherm™ Probe and Monitor – the SensiTherm Esophageal Temperature Monitoring System enables physicians to monitor the temperature of the esophagus during ablation procedures, providing the critical information necessary to adapt therapy as needed.
• EnSite Velocity™ System – the only cardiac mapping system designed to offer workflow efficiency through the combination of one-step high-density map creation and intuitive and simple setup and operation. The EnSite Velocity System maintains an open platform, which is compatible with nearly all diagnostic and ablation catheters, recording systems and energy sources used for ablation procedures.

In addition, because of the company’s long history of product safety, effectiveness and innovation, there will be a focus at the booth on the ongoing clinical research performed by St. Jude Medical. Highlights will include information about studies in progress and cutting-edge data that support unique approaches to address today’s clinical objectives.

Also launching at HRS is the new SJMprofessional.com Web site, which allows our cardiac medical professional customers to stay current with global technology news and information, discover educational opportunities and access online libraries related to device therapies. The site features in-depth medical insights from physician thought-leaders using clinical evidence and case studies to present product information and treatment options.

In addition to new devices and technologies, St. Jude Medical will feature the following speakers in the company’s booth:

Thursday, May 14

CRM Theater

9:15 a.m. – Jennifer Cohen, M.D., "MagnaSafe Registry and MRI Conditional Pacemakers”

9:50 a.m. – Rafael Corbisiero, M.D., "Advancements in ICD Lead Design”

1:30 p.m. – Harry Mond, M.D., "Right Ventricular Septal Pacing”

2:05 p.m. – Thorsten Lewalter, M.D., "Syncope Disease Management”

2:40 p.m. – Sumit Mittal, M.D., "Taking the Next Step in Remote Patient Management”

AF Theater

9:15 a.m. – Steve Kalbfleisch, M.D., "Agilis NxT Steerable Introducer for Mapping and Ablation”

9:50 a.m. – Adam Berman, M.D., "Use of the EnSite Array for Inappropriate Sinus Tachycardia”

1:30 p.m. – Lin Fang-yue, M.D., "Use of Advanced Electrogram Tools”

2:05 p.m. – Bruce Hook, M.D., "EP Procedures with EnSite CoHesion and Hansen”

2:40 p.m. – Fermin Garcia, M.D., "Use of High Frequency Ventilation in EP Procedures”

Friday, May 15

CRM Theater

9:35 a.m. – Georg Nolker, M.D., "AVOID FFS: Study of the Unique and Novel Atrial Lead with 1.1 mm Tip-to-Ring Spacing”

10:10 a.m. – Jay Gross, M.D., "System Safeguards in ICDs”

10:45 a.m. – Betty Ching, RN, "Remote Monitoring and Workflow – Is Niagara Falling?”

11:20 a.m. – Johannes Sperzel, M.D., "Clinical Relevance of Ischemia and Ventricular Arrhythmias”

11:55 a.m. – Niuton Koide, M.D., "Clinical Experience with Novel Left Ventricular Lead Delivery Tools”

AF Theater

9:35 a.m. – Kousik Krishnan, M.D., "Steerable Sheath Catheter Navigation for Ablation”

10:10 a.m. – Tony Chow, M.D., "Initial Experience with New High Density Mapping Catheter”

10:45 a.m. – John Clark, M.D., "Managing Complex Arrhythmias with the EnSite System”

11:20 a.m. – J. Michael Mangrum, M.D., "Advanced Techniques for Registration Using Fusion”

11:55 a.m. – Sunil Shroff, M.D., "Application of EnSite Array for Atrial Flutter”

At Heart Rhythm 2009, St. Jude Medical will also sponsor three continuing medical education (CME) symposia: "Treatment Strategies and Outcomes for Repeat Atrial Fibrillation Procedures,” which will be chaired by John D. Day, M.D., of the Intermountain Medical Center, Salt Lake City, Utah, on Wednesday, May 13; "The Future of Ambulatory Monitoring: Moving Beyond Rate and Rhythm to Monitor ST-Segment Shifts,” which will be chaired by C. Michael Gibson, M.D., of the Harvard Medical School, Boston, also on Wednesday, May 13; and "The Great Debate: A Point Counterpoint Discussion on Issues Impacting Today’s Electrophysiology Lab,” chaired by Vivek Reddy, M.D., of University of Miami Miller School of Medicine, Fla. and Pierre Jais, M.D., of Hopital Haut Lévêque, in Bordeaux, France on Thursday, May 14.

Heart Rhythm 2009 takes place May 13-16 at the Boston Exhibition and Convention Center. The meeting is the most comprehensive educational event on heart rhythm disorders, offering approximately 250 educational opportunities in multiple formats. The world’s most renowned scientists and physicians will present a wide range of heart rhythm topics including cardiac resynchronization therapy, catheter ablation, cardiac pacing and heart failure and the latest technology, including state-of-the-art pacemakers and defibrillators. www.HRSonline.org.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs approximately 14,000 people worldwide and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit www.sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended April 4, 2009. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.